KR100838253B1 - Composition for enhancing learning or memory comprising loganin or its salt - Google Patents
Composition for enhancing learning or memory comprising loganin or its salt Download PDFInfo
- Publication number
- KR100838253B1 KR100838253B1 KR1020070050782A KR20070050782A KR100838253B1 KR 100838253 B1 KR100838253 B1 KR 100838253B1 KR 1020070050782 A KR1020070050782 A KR 1020070050782A KR 20070050782 A KR20070050782 A KR 20070050782A KR 100838253 B1 KR100838253 B1 KR 100838253B1
- Authority
- KR
- South Korea
- Prior art keywords
- memory
- learning
- salt
- composition
- loganin
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 230000028252 learning or memory Effects 0.000 title claims abstract description 20
- 230000002708 enhancing effect Effects 0.000 title claims abstract 4
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 title abstract description 14
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 title abstract description 11
- 230000015654 memory Effects 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 17
- 208000026139 Memory disease Diseases 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 239000003937 drug carrier Substances 0.000 claims abstract description 13
- 229920005610 lignin Polymers 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 206010027175 memory impairment Diseases 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000013016 learning Effects 0.000 abstract description 15
- 201000003723 learning disability Diseases 0.000 abstract description 15
- 208000020358 Learning disease Diseases 0.000 abstract description 13
- 241000699670 Mus sp. Species 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 6
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 6
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 6
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 6
- 229960002646 scopolamine Drugs 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- AMBQHHVBBHTQBF-DLXIZZNVSA-N methyl 6-hydroxy-7-methyl-1-[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate Chemical compound C12C(C)C(O)CC2C(C(=O)OC)=COC1O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O AMBQHHVBBHTQBF-DLXIZZNVSA-N 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000019771 cognition Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- -1 liquid paraffin Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000006993 memory improvement Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- GKNRELVWAMNDAS-UHFFFAOYSA-N 6-amino-4-oxo-1h-pyrimidine-5-carbonitrile Chemical class NC=1NC=NC(=O)C=1C#N GKNRELVWAMNDAS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000027326 copulation Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
도 1 은 마우스에서 로가닌이 스코폴아민 유도 건망증에 미치는 억제효과를 나타낸다.1 shows the inhibitory effect of loganan on scopolamine-induced forgetfulness in mice.
도 2는 마우스에서 로가닌에 의한 학습 및 기억력 개선효과를 나타낸다.Figure 2 shows the effect of improving the learning and memory by Loganin in the mouse.
본 발명은 로가닌 또는 그의 염 및 약제학적으로 허용가능한 담체를 포함하는, 학습 장애 또는 기억력 장애의 예방 또는 치료용 약학 조성물 또는 학습 또는 기억력 증진용 약학 조성물에 관한 것이다. 또한, 본 발명은 로가닌 또는 그의 염을 유효성분으로 포함하는, 학습 장애 또는 기억력 장애의 예방 또는 치료용 식품 조성물 또는 학습 또는 기억력 증진용 식품 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for preventing or treating learning disorders or memory disorders or a pharmaceutical composition for improving learning or memory, comprising logannin or a salt thereof and a pharmaceutically acceptable carrier. The present invention also relates to a food composition for preventing or treating learning disorders or memory disorders or a food composition for improving learning or memory, comprising logannin or a salt thereof as an active ingredient.
기억이란 주위환경으로부터 얻은 새로운 정보나 학습된 경험, 지식을 습득하여 이를 뇌의 특정부위에 부호화하여 저장하고 이를 다시 회상하는 과정을 말한다(William F Ganong; Ganong's 생리학, 서울, 한우리, p289, p291-292, 1999). 기 억의 과정은 습득, 부호화, 강화, 유지, 회상의 여러 단계로 구분된다. Memory refers to the process of acquiring new information, learned experiences, and knowledge from the environment, encoding it in specific parts of the brain, storing it, and recalling it (William F Ganong; Ganong's Physiology, Seoul, Hanwoori, p289, p291-). 292, 1999). The process of memory is divided into several stages: acquisition, encoding, reinforcement, maintenance, and recall.
현대사회는 복잡하고 전문화되는 추세이며 그에 따라 많은 정보량과 학습량이 요구되므로 효과적인 두뇌활동이 필요하게 된다. 또한 많은 사람들이 노화 및 질병에 의한 기억력의 감퇴로 고통받고 있으며 인간의 수명이 연장되어 감에 따라 고도의 정신활동이 요구되고 있다. 이러한 상황을 적절히 대처하기 위하여 두뇌를 맑게 하고 기억력을 증진시켜 정신활동을 필요로 하는 등의 노력이 다양하게 시도되고 있고 이러한 기능을 효과적으로 증진시킬 수 있는 의약품, 기능성 식품등의 개발이 당업계에 요구되고 있다.Modern society is a complex and specialized trend, and accordingly, a large amount of information and learning amount is required, and therefore effective brain activity is required. In addition, many people suffer from memory loss due to aging and disease, and high mental activity is required as the life span of human beings is extended. In order to cope with this situation, various efforts have been made to clear the brain, improve memory, and require mental activities, and the development of medicines, functional foods, etc. that can effectively promote these functions is required in the art. It is becoming.
대한민국 특허공개 제10-2007-0015372호는 인지, 집중, 학습 및(또는) 기억의 손상의 예방 및(또는) 치료에 유용한 6-아미노-5-시아노-피리미딘-4-온 유도체를 개시한 바 있다. Korean Patent Publication No. 10-2007-0015372 discloses 6-amino-5-cyano-pyrimidin-4-one derivatives useful for the prevention and / or treatment of impairment of cognition, concentration, learning and / or memory. I've done it.
본 발명자들은 학습 능력 및/또는 기억력을 증진시킬 수 있는 안전성이 확보된 천연물 유래의 화합물을 대상으로 다양한 검색을 수행하였다. 그 결과, 산수유, 호미카 등에 함유된 것으로 알려져 있는 배당체인 로가닌이 우수한 학습 능력 및/또는 기억력 증진 효과를 갖는다는 것을 발견하였다.The present inventors conducted various searches for compounds derived from natural products that have secured safety that can enhance learning ability and / or memory. As a result, it was found that the glycan, a glycoside known to be contained in Cornus, Homica and the like, has an excellent learning ability and / or memory enhancement effect.
따라서, 본 발명은 로가닌 또는 그의 염 및 약제학적으로 허용가능한 담체를 포함하는, 학습 장애 또는 기억력 장애의 예방 또는 치료용 약학 조성물 또는 학습 또는 기억력 증진용 약학 조성물을 제공하는 것을 목적으로 한다.Accordingly, an object of the present invention is to provide a pharmaceutical composition for preventing or treating learning disorders or memory disorders or a pharmaceutical composition for improving learning or memory, comprising logannin or a salt thereof and a pharmaceutically acceptable carrier.
또한, 본 발명은 로가닌 또는 그의 염을 유효성분으로 포함하는, 학습 장애 또는 기억력 장애의 예방 또는 치료용 식품 조성물 또는 학습 또는 기억력 증진용 식품 조성물을 제공하는 것을 목적으로 한다.In addition, an object of the present invention is to provide a food composition for preventing or treating learning disorders or memory disorders or a food composition for learning or memory enhancement, comprising a lignin or a salt thereof as an active ingredient.
본 발명의 일 태양에 따라, 로가닌 또는 그의 염 및 약제학적으로 허용가능한 담체를 포함하는, 학습 장애 또는 기억력 장애의 예방 또는 치료용 약학 조성물이 제공된다.According to one aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating learning disorders or memory disorders, comprising logannin or a salt thereof and a pharmaceutically acceptable carrier.
본 발명의 다른 태양에 따라, 로가닌 또는 그의 염 및 약제학적으로 허용가능한 담체를 포함하는, 학습 또는 기억력 증진용 약학 조성물이 제공된다.According to another aspect of the present invention, there is provided a pharmaceutical composition for improving learning or memory, comprising logannin or a salt thereof and a pharmaceutically acceptable carrier.
본 발명의 또 다른 태양에 따라, 로가닌 또는 그의 염을 유효성분으로 포함하는, 학습 장애 또는 기억력 장애의 예방 또는 치료용 식품 조성물이 제공된다.According to still another aspect of the present invention, there is provided a food composition for preventing or treating learning disorders or memory disorders, which comprises logannin or a salt thereof as an active ingredient.
본 발명의 다른 태양에 따라, 로가닌 또는 그의 염 및 약제학적으로 허용가능한 담체를 포함하는, 학습 또는 기억력 증진용 식품 조성물이 제공된다.According to another aspect of the present invention, there is provided a food composition for learning or memory enhancement, comprising logannin or a salt thereof and a pharmaceutically acceptable carrier.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 명세서에서, "학습(learning)" 이라 함은 자신의 행동을 지각하고 변화시킬 수 있는 능력 또는 행동을 말하며, 공간지각력, 인지력, 집중력 등을 포함한다.As used herein, "learning" refers to an ability or behavior that can perceive and change one's own behavior, and includes spatial perception, cognition, concentration, and the like.
"학습 장애(learning disorder 혹은 learning disability)"라 함은 지능 지수와 관계없이 다양한 원인, 예를 들어 우울증, 불안증, 강박증, 사회환경적 요인(가정불화, 빈곤, 결손가정, 스트레스) 등에 의해 "학습" 능력이 정상인에 비해 낮아진 상태를 말하며, 공간지각력 저하, 인지력 저하, 집중력 저하, 아동 등의 학업 성취도 저하 등을 포함한다."Learning disorder or learning disability" refers to "learning disorder or learning disability" due to a variety of causes, regardless of IQ, for example, depression, anxiety, obsessive compulsive disorder, social and environmental factors (failure, poverty, missing family, stress, etc.). "Ability is lowered than normal, and it includes a decrease in spatial perception, a decrease in cognition, a concentration, and a decrease in academic achievement of children.
"기억" 또는 "기억력" 이라 함은 주위 환경으로부터 얻은 새로운 정보나 학습된 경험, 지식을 습득하여 뇌의 특정부위에 부호화하여 저장하고 이를 다시 회상할 수 있는 능력을 말한다.The term "memory" or "memory" refers to the ability to acquire new information, learned experience, and knowledge from the environment, encode it in a specific area of the brain, store it, and recall it.
"기억력 장애(memory disorder 혹은 memory deficiency)" 라 함은 외상, 주의력 결핍, 노화, 질병 등의 다양한 원인에 의하여 상기 "기억력"이 정상인에 비해 낮아진 상태를 말하며, 건망증(amnesia), 집중력 장애, 공간지각력 손실, 학습능력의 둔화, 인지력 상실 등을 포함한다."Memory disorder" or "memory deficiency" refers to a condition in which the "memory" is lowered than a normal person due to various causes such as trauma, attention deficit, aging, disease, etc., amnesia, concentration disorder, space Loss of perception, slowing learning, loss of cognition.
본 발명에 의해, 로가닌 또는 그의 염이 학습 장애 또는 기억력 장애를 예방 또는 치료할 수 있으며, 또한 학습 또는 기억력을 증진시키는 것이 새롭게 발견되었다. 로가닌을 투여한 경우 스코폴아민에 의해 유도된 건망증에 대하여 현저히 증가된 학습 및/또는 기억력을 나타내었으며, 전기 충격에 의한 체재시간 측정 시험에서 로가닌을 투여한 마우스가 현저히 우수한 학습 또는 기억력 증진 효과를 나타내었다.With the present invention, it has been newly discovered that logannin or salts thereof can prevent or treat learning or memory disorders, and also enhance learning or memory. The administration of loganan showed significantly increased learning and / or memory for scopolamine-induced forgetfulness, and the mice treated with loganan showed significantly better learning or It showed a memory enhancing effect.
본 발명은 로가닌 또는 그의 염 및 약제학적으로 허용가능한 담체를 포함하는, 학습 장애 또는 기억력 장애의 예방 또는 치료용 약학 조성물을 포함한다. 또한, 본 발명은 로가닌 또는 그의 염 및 약제학적으로 허용가능한 담체를 포함하는, 학습 또는 기억력 증진용 약학 조성물을 포함한다.The present invention includes a pharmaceutical composition for the prevention or treatment of learning or memory disorders, comprising logannin or a salt thereof and a pharmaceutically acceptable carrier. In addition, the present invention includes a pharmaceutical composition for improving learning or memory, comprising logannin or a salt thereof and a pharmaceutically acceptable carrier.
상기 로가닌은 그 화학명이 7-히드록시-6-데스옥시베르메날린(7-Hydroxy-6-desoxyverbenalin)으로서, 하기 화학식 1의 구조를 갖는다.Loganin has the chemical name of 7-hydroxy-6-desoxyverbenalin (7-Hydroxy-6-desoxyverbenalin), and has the structure of Formula 1 below.
상기 로가닌은 호미카(Strychni Semen)로부터 분리될 수 있으며(Dunstan, Short, Pharm. J. 14, 1025, 1883), 다양한 합성방법이 공지되어 있다. 상기 로가닌의 염으로는 통상의 무독성 염을 포함하며, 예를 들어 염산염, 황산염, 말레산염(maleate), 소듐염, 탄산염, 타르트산염(tartrate), 바이타르트산염(bitartrate), 질산염(nitrate), 벤조산염(benzoate), 라이신염(lysine), 구연산염(citrate), 브롬산염(bromide), 수소화브롬산염(hydrobromide) 등을 포함한다. The loganine can be isolated from Strychni Semen (Dunstan, Short, Pharm. J. 14, 1025, 1883), and various methods of synthesis are known. The salts of loganin include conventional non-toxic salts, for example hydrochloride, sulfate, maleate, sodium salt, carbonate, tartrate, bitartrate, nitrate ), Benzoate, lysine, citrate, bromide, hydrobromide, and the like.
본 발명에 따른 조성물은 약제학적으로 허용가능한 담체를 포함하여 약학 조성물로 제제화될 수 있으며, 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제제화될 수 있다. The composition according to the invention may be formulated into a pharmaceutical composition comprising a pharmaceutically acceptable carrier, oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc. according to conventional methods, It may be formulated in the form of external preparations, suppositories, and sterile injectable solutions.
상기 약제학적으로 허용가능한 담체는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이 트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한다. 또한, 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 포함한다. 경구용 고형 제제는 정제, 환제, 산제, 과립제, 캡슐제 등을 포함하며, 이러한 고형제제는 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 포함할 수 있으며, 마그네슘 스테아레이트, 탈크 같은 윤활제 등을 포함할 수 있다. 경구용 액상 제제는 현탁제, 내용액제, 유제, 시럽제 등을 포함하며, 물, 리퀴드 파라핀 등의 희석제, 습윤제, 감미제, 방향제, 보존제 등을 포함할 수 있다. 비경구용 제제는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제를 포함하며, 비수성 용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르류 등을 포함한다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The pharmaceutically acceptable carrier is lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. Also included are diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, and the like. Oral solid preparations include tablets, pills, powders, granules, capsules and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose or lactose. ), Gelatin, and the like, and may include a lubricant such as magnesium stearate, talc, and the like. Oral liquid preparations include suspensions, solvents, emulsions, syrups, and the like, and may include water, diluents such as liquid paraffin, wetting agents, sweeteners, fragrances, preservatives, and the like. Parenteral preparations include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and ethyl. Injectable esters such as oleate and the like. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 약학조성물에 함유되는 로가닌 또는 그의 염의 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 예를 들면, 상기 로가닌 또는 그의 염은 1일 0.01 내지 500 mg/kg으로, 바람직하게는 10 내지 100 mg/kg의 용량으로 투여할 수 있으며, 상기 투여는 하루에 한번 또는 수회 나누어 투여할 수도 있다. 또한, 본 발명의 약학 조성물은 조성물 총 중량에 대하여 상기 로가닌 또는 그의 염을 0.001 내지 50 % 중량백분율로 포함할 수 있다. The dosage of loganan or a salt thereof contained in the pharmaceutical composition of the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. For example, the loganine or salt thereof may be administered at a dose of 0.01 to 500 mg / kg, preferably 10 to 100 mg / kg, and the administration may be administered once or several times a day. It may be. In addition, the pharmaceutical composition of the present invention may comprise 0.001 to 50% by weight of the lignin or salt thereof relative to the total weight of the composition.
본 발명은 로가닌 또는 그의 염을 유효성분으로 포함하는, 학습 장애 또는 기억력 장애의 예방 또는 치료용 식품 조성물을 포함한다. 또한, 본 발명은 로가닌 또는 그의 염을 유효성분으로 포함하는, 학습 또는 기억력 증진용 식품 조성물을 포함한다.The present invention includes a food composition for the prevention or treatment of learning disorders or memory disorders, including lignin or a salt thereof as an active ingredient. In addition, the present invention includes a food composition for learning or memory enhancement, comprising logannin or a salt thereof as an active ingredient.
본 발명의 식품 조성물은 건강기능식품으로서 사용될 수 있다. 상기 "건강기능식품"이라 함은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.The food composition of the present invention can be used as a dietary supplement. The term "health functional food" means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to Act No. 6767 of the Health Functional Food Act, and "functionality" refers to the structure of the human body. And ingestion for the purpose of obtaining nutrients for function or for obtaining useful effects in health uses such as physiological actions.
본 발명의 식품 조성물은 통상의 식품 첨가물을 포함할 수 있으며, 상기 "식품 첨가물"로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안정청에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다. The food composition of the present invention may include a conventional food additives, and the suitability as the "food additives", unless otherwise specified, corresponding items according to the General Regulations and General Test Methods of the Food Additives approved by the Food and Drug Administration It is determined by the standard and the standard.
상기 "식품 첨가물 공전"에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성물, 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류들을 들 수 있다.Examples of the items listed in the "Food Additive Revolution" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamon acid, natural additives such as color pigments, licorice extracts, crystalline cellulose, high color pigments, guar gum, Mixed preparations, such as a sodium L- glutamate preparation, an addition of an alkali, a preservative preparation, and a tar pigment preparation, are mentioned.
본 발명의 식품 조성물은 학습 장애 또는 기억력 장애의 예방 또는 치료를 목적으로 또는 학습 또는 기억력 증진을 목적으로, 조성물 총 중량에 대하여 로가닌 또는 그의 염을 0.01 내지 95 %, 바람직하게는 1 내지 80 % 중량백분율로 포함 할 수 있다. 또한, 학습 장애 또는 기억력 장애의 예방 또는 치료를 목적으로 또는 학습 또는 기억력 증진을 목적으로, 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공할 수 있다.The food composition of the present invention is 0.01 to 95%, preferably 1 to 80% of lignin or a salt thereof, based on the total weight of the composition, for the purpose of preventing or treating learning disorders or memory disorders or for the purpose of improving learning or memory. It can be included as a percentage by weight. In addition, it may be prepared and processed in the form of tablets, capsules, powders, granules, liquids, pills and the like for the purpose of preventing or treating learning disorders or memory disorders or for the purpose of improving learning or memory.
예를 들어, 상기 정제 형태의 건강기능식품은 로가닌 또는 그의 염, 부형제, 결합제, 붕해제, 및 다른 첨가제와의 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축성형하거나, 상기 혼합물을 직접 압축성형할 수 있다. 또한, 상기 정제 형태의 건강기능식품은 필요에 따라 교미제 등을 함유할 수 있으며, 필요에 따라 적당한 제피제로 제피할 수도 있다.For example, the health functional food in the form of tablets may be formed by granulating a mixture of rogannine or its salts, excipients, binders, disintegrants, and other additives in a conventional manner, and then compression molding with a lubricant or the like. The mixture may be directly compression molded. In addition, the health functional food in the form of tablets may contain a mating agent and the like, if necessary, may be coated with a suitable coating agent.
캅셀 형태의 건강기능식품 중 경질캅셀제는 통상의 경질캅셀에 로가닌 또는 그의 염 및 부형제 등의 첨가제와의 혼합물 또는 그의 입상물 또는 제피한 입상물을 충진하여 제조할 수 있으며, 연질캅셀제는 로가닌 또는 그의 염 및 부형제 등의 첨가제와의 혼합물을 젤라틴 등 캅셀기제에 충진하여 제조할 수 있다. 상기 연질캅셀제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다.Hard capsules of the health functional food in the form of capsules may be prepared by filling a conventional hard capsule with a mixture of additives such as roganine or its salts and excipients, or granules or avoided granules thereof. It can be prepared by filling a capsule base such as gelatin with a mixture of additives such as ganine or salts thereof and excipients. The soft capsule agent may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, as necessary.
환 형태의 건강기능식품은 로가닌 또는 그의 염, 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 적당한 제피제로 제피를, 또는 전분, 탈크 또는 적당한 물질로 환의를 입힐 수도 있다.The dietary supplement in cyclic form can be prepared by molding a mixture of logannin or its salts, excipients, binders, disintegrants, etc. in a suitable manner. Or they may be greeted with a suitable substance.
과립형태의 건강기능식품은 상기 로가닌 또는 그의 염, 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착 향제, 교미제 등을 함유할 수 있다.The health functional food in the form of granules may be prepared into granules by a suitable method, such as a mixture of lignin or a salt thereof, an excipient, a binder, a disintegrating agent, and may contain a flavoring agent, a copper, and the like as necessary.
본원 발명의 상기 부형제, 결합제, 붕해제, 활택제, 교미제, 착향제 등에 대한 용어 정의는 당업계에 공지된 문헌에 기재된 것으로 그 기능 등이 동일 내지 유사한 것들을 포함한다 (대한약전 해설편, 문성사, 한국약학대학협의회, 제 5 개정판, p33-48, 1989).The term definitions of the excipients, binders, disintegrants, glidants, copulation agents, flavoring agents, etc. of the present invention are described in documents known in the art and include those having the same or similar functions. Sacrament, Korean College of Pharmacy, 5 revised edition, p33-48, 1989).
이하, 본 발명을 실시예 및 시험예를 통하여 더욱 상세히 설명한다. 그러나 이들 실시예 및 시험예는 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예 및 시험예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through Examples and Test Examples. However, these Examples and Test Examples are for illustrating the present invention, and the scope of the present invention is not limited to these Examples and Test Examples.
실시예Example ..
6주령의 ICR계 수컷 마우스(22 - 27 g)를 MJ LTD (서울, 대한민국)에서 공급받아 성균관대학교 약학대학의 동물사육실에서 1주일 이상 사육하여 적응시켜 사용하였으며, 물과 사료는 자유롭게 섭취하도록 하였고, 온도 (23 ± 2 ℃), 습도 (55 ± 10 %) 및 명암주기 (12 시간)는 자동으로 조절되도록 하였다. 로가닌은 Extrasynthese 사(프랑스)에서 구입하여 사용하였다.Six-week-old male ICR mice (22-27 g) were supplied by MJ LTD (Seoul, South Korea) and used in the animal breeding room of Sungkyunkwan University Pharmacy for more than a week. Temperature (23 ± 2 ° C), humidity (55 ± 10%) and contrast cycle (12 hours) were automatically adjusted. Loganin was purchased from Extrasynthese (France).
실시예Example 1. One. 로가닌의Loganine 스코폴아민Scopolamine 유도 건망증 개선 효과 Induced forgetfulness
마우스를 각 군당 10 마리씩 5 군으로 나누었다. 제1군(대조군)은 생리식염수 투여군, 제2군은 식염수 및 스콜폴라민 투여군, 제3군 내지 제5군은 각각 로가닌 10, 20, 40 mg/kg 및 스코폴아민 투여군으로 하였다.Mice were divided into 5 groups, 10 of each group. The first group (control) was a saline-administered group, the second group was a saline and scopolamine-administered group, and the third to fifth groups were 10, 20, 40 mg / kg and scopolamine-administered groups, respectively.
로가닌을 생리식염수에 용해시켜 10, 20, 40 mg/kg의 용량으로 마우스에 경구투여하고, 30분 후에 스코폴아민 0.25 mg/kg을 피하주사 하였다. 30분 후에 마우스를 스텝-스루(step-through) 장치에 넣어 어두운 상자로 들어가면 0.4 mA (2 초)의 전기 충격을 가하여 학습(training)시켰다. 24 시간 후에 마우스를 다시 밝은 상자에 넣어 검은 상자에 들어가기까지의 체재시간을 측정하여 스코폴아민 유도 건망증에 대한 학습 및 기억력의 지표로 하였다. 이때 마우스의 컷-오프 시간(cut-off time)은 300초로 하여 대조군과 비교하였다. 시험 결과는 도 1과 같다.Loganin was dissolved in physiological saline and orally administered to mice at doses of 10, 20, 40 mg / kg, and after 30 minutes, scopolamine 0.25 mg / kg was injected subcutaneously. After 30 minutes the mice were placed in a step-through device into a dark box and trained by applying an electric shock of 0.4 mA (2 seconds). After 24 hours, the mice were placed in bright boxes again to measure the length of time until they entered the black boxes, which were used as indicators of learning and memory about scopolamine-induced forgetfulness. At this time, the cut-off time of the mouse was set to 300 seconds and compared with the control group. The test results are shown in FIG. 1.
생리식염수 대조군은 207초를 나타내어 기억력이 유지되고 있으나 스코폴아민 투여 대조군은 시험일에 64 초의 체재시간을 나타내어 건망증이 현저히 유도되었으며(p<0.05), 로가닌 10 mg/kg 투여군은 139초를 나타내어 체재시간을 75초 증가시켰으며, 20 mg/kg 투여군은 196초를 나타내어 마우스의 체재시간을 132초 증가시켰다(p<0.05). 따라서 로가닌의 투여는 저하된 마우스의 학습 및 기억력을 용량의존적으로 현저히 증가시켰다.The physiological saline control group showed memory retention of 207 seconds, while the control group of scopolamine showed 64 seconds of stay time on the test day, leading to forgetfulness (p <0.05). In addition, the stay time was increased by 75 seconds, and the 20 mg / kg administration group showed 196 seconds, which increased the stay time of mice by 132 seconds (p <0.05). Therefore, administration of loganin significantly increased dose-dependently the learning and memory of degraded mice.
실시예Example 2. 2. 로가닌의Loganine 학습 및 기억력 개선 효과 Learning and memory improvement
마우스를 각 군당 10 마리씩 3 군으로 나누었다. 제1군은 생리식염수 투여군, 제2군 및 제3군은 각각 로가닌 10 및 40 mg/kg 투여군으로 하였다.Mice were divided into 3 groups, 10 of each group. The first group was a saline-administered group, the second group and the third group were 10 and 40 mg / kg administration group, respectively.
로가닌을 생리식염수에 용해시켜 10 및 40 mg/kg의 용량으로 마우스에 경구투여하고, 30분 후에 마우스를 스텝-스루(step-through) 장치에 넣어 어두운 상자로 들어가면 0.15 mA (2 초)의 전기 충격을 가하여 학습(training)시켰다. 24 시간 후에 마우스를 다시 밝은 상자에 넣어 검은 상자에 들어가기까지의 체재시간을 측정하여 학습 및 기억력의 지표로 하였다. 이때 마우스의 컷-오프 시간(cut-off time)은 300초로 하여 대조군과 비교하였다. 시험 결과는 도 2와 같다.Loganine was dissolved in physiological saline and orally administered to mice at doses of 10 and 40 mg / kg, and after 30 minutes the mouse was placed in a step-through device into a dark box at 0.15 mA (2 seconds). Trained by applying an electric shock. After 24 hours, the mice were placed in bright boxes again, and the stay time until entering the black boxes was measured as an index of learning and memory. At this time, the cut-off time of the mouse was set to 300 seconds and compared with the control group. The test results are shown in FIG. 2.
대조군의 마우스는 시험일에 38초의 체재시간을 나타내었으며, 로가닌 10 mg/kg 투여군은 177초를 나타내어 체재시간을 139초 증가시켰으며(p<0.01), 40 mg/kg 투여군은 203초를 나타내어 마우스의 체재시간을 165초 증가시켜(p<0.01) 용량의존적으로 마우스의 학습 및 기억력을 현저히 증가시켰다.The mice in the control group had a stay time of 38 seconds on the test day, and the loganin 10 mg / kg group showed 177 seconds, increasing the stay time by 139 seconds (p <0.01), and the 40 mg / kg group received 203 seconds. Increasing the stay time of the mice by 165 seconds (p <0.01) significantly increased the learning and memory of the mice in a dose-dependent manner.
로가닌 또는 그의 염을 포함하는 본 발명에 따른 약학 조성물 및/또는 식품 조성물은 학습 장애 또는 기억력 장애를 예방 또는 치료할 수 있으며, 또한 학습 또는 기억력을 증진시킨다.The pharmaceutical composition and / or food composition according to the present invention comprising logannin or salts thereof can prevent or treat learning disorders or memory disorders, and also enhance learning or memory.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070050782A KR100838253B1 (en) | 2007-05-25 | 2007-05-25 | Composition for enhancing learning or memory comprising loganin or its salt |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070050782A KR100838253B1 (en) | 2007-05-25 | 2007-05-25 | Composition for enhancing learning or memory comprising loganin or its salt |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100838253B1 true KR100838253B1 (en) | 2008-06-17 |
Family
ID=39771396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070050782A KR100838253B1 (en) | 2007-05-25 | 2007-05-25 | Composition for enhancing learning or memory comprising loganin or its salt |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100838253B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200008724A (en) | 2018-07-17 | 2020-01-29 | 동아대학교 산학협력단 | Composition for preventing or treating neurodegenerative disease comprising cardamonin |
KR20200053370A (en) | 2018-11-08 | 2020-05-18 | 동아대학교 산학협력단 | Composition for preventing or treating neurodegenerative disease comprising phlorotannin |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050005630A (en) * | 2003-07-07 | 2005-01-14 | 주식회사 엠디바이오알파 | Lonicera japonica extract having activity of enhancing IGF-1 secretion, its process method, and application |
JP2007001972A (en) | 2005-05-25 | 2007-01-11 | Mitsukan Group Honsha:Kk | Quiet sleep-inducing composition |
-
2007
- 2007-05-25 KR KR1020070050782A patent/KR100838253B1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050005630A (en) * | 2003-07-07 | 2005-01-14 | 주식회사 엠디바이오알파 | Lonicera japonica extract having activity of enhancing IGF-1 secretion, its process method, and application |
JP2007001972A (en) | 2005-05-25 | 2007-01-11 | Mitsukan Group Honsha:Kk | Quiet sleep-inducing composition |
Non-Patent Citations (1)
Title |
---|
J. of Ethnopharmacology 106(2006) 166-172 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200008724A (en) | 2018-07-17 | 2020-01-29 | 동아대학교 산학협력단 | Composition for preventing or treating neurodegenerative disease comprising cardamonin |
KR20200053370A (en) | 2018-11-08 | 2020-05-18 | 동아대학교 산학협력단 | Composition for preventing or treating neurodegenerative disease comprising phlorotannin |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7968128B2 (en) | Plant extract compositions for affecting sleep | |
JP4989775B2 (en) | Peptides with brain function improving action | |
AU2015384083B2 (en) | Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome | |
WO2002074295A1 (en) | A composition for the prophylaxis or treatment of senile dementia | |
KR20110005144A (en) | Pharmaceutical composition and health-food composition containing ginseng extracts having neuroprotective effects | |
TWI329018B (en) | Anti-stress agent | |
KR100838253B1 (en) | Composition for enhancing learning or memory comprising loganin or its salt | |
KR20170067466A (en) | Composition for preventing or treating dementia or improving cognitive ability comprising spirulina extract | |
KR20180126231A (en) | A composition comprising herbal mixture extract for neuroprotection | |
TW201106959A (en) | Composition for preventing or treating irritable bowel syndrome | |
KR20110123114A (en) | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease | |
KR101045025B1 (en) | Pharmaceutical composition for preventing or treatment of asthma | |
KR101989739B1 (en) | Composition for preventing or treating diabetes mellitus comprising Rorippa globosa extracts | |
JP5358627B2 (en) | A pharmaceutical composition for preventing or treating ischemic disease or degenerative brain disease, or for improving memory impairment, comprising Tarayo extract as an active ingredient | |
JP2011136932A (en) | Composition for improving cerebral function and method for improving cerebral function | |
JP5634062B2 (en) | Composition for improving brain function and method for improving brain function | |
WO2012131643A1 (en) | Herbal compositions comprising pedilanthus tithymaloides for treatment prevention of gastrointestinal disorder | |
TWI492756B (en) | Compositions and methods for improving brain function | |
KR20100092824A (en) | Pharmaceutical composition comprising chlorogenic acid or its salt as effective ingredient for preventing or treating of learning or memory disorder, or dementia | |
JP2013515716A (en) | Compositions containing the extract of peony for preventing and treating ADHD diseases and uses thereof | |
CN101549125A (en) | Pharmaceutical composition used for treating peculiar smell of oral cavity and preparation method thereof | |
KR101894540B1 (en) | Composition for improving coenzyme Q10 with extract of Pinellia ternata, Atractylodes macrocephala, Gastrodia elata, Citrus unshiu peel, Poria cocos, Crataegus pinnatifida, Siegesbeckia pubescens Makino and Coptis japonica Makino | |
WO2012036191A1 (en) | Composition for improving brain function and method for improving brain function | |
KR101106376B1 (en) | A composition comprising the extract of dictyota coriacea treating and preventing neuro-degenerative disease | |
KR102651825B1 (en) | Composition for improving Memory and cognitive function and composition for preventing or improving Alzheimer's disease containing policosanol as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120425 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20130409 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |